AU2007319820B2 - In vitro expansion of postpartum-derived cells using microcarriers - Google Patents
In vitro expansion of postpartum-derived cells using microcarriers Download PDFInfo
- Publication number
- AU2007319820B2 AU2007319820B2 AU2007319820A AU2007319820A AU2007319820B2 AU 2007319820 B2 AU2007319820 B2 AU 2007319820B2 AU 2007319820 A AU2007319820 A AU 2007319820A AU 2007319820 A AU2007319820 A AU 2007319820A AU 2007319820 B2 AU2007319820 B2 AU 2007319820B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- microcarriers
- cell
- microcarrier
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000338 in vitro Methods 0.000 title description 8
- 238000000034 method Methods 0.000 claims abstract description 110
- 230000012010 growth Effects 0.000 claims abstract description 77
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 239000001963 growth medium Substances 0.000 claims description 103
- 230000001419 dependent effect Effects 0.000 claims description 57
- 108010035532 Collagen Proteins 0.000 claims description 56
- 102000008186 Collagen Human genes 0.000 claims description 56
- 229920001436 collagen Polymers 0.000 claims description 56
- 210000002966 serum Anatomy 0.000 claims description 35
- 239000000463 material Substances 0.000 claims description 34
- 230000003068 static effect Effects 0.000 claims description 31
- 238000002659 cell therapy Methods 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 19
- -1 CD31 Proteins 0.000 claims description 18
- 238000012258 culturing Methods 0.000 claims description 16
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 15
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 15
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 13
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 13
- 102100032912 CD44 antigen Human genes 0.000 claims description 13
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 13
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 13
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 13
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 12
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 12
- 210000003954 umbilical cord Anatomy 0.000 claims description 12
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 11
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 11
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 11
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 11
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 11
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 11
- 230000010261 cell growth Effects 0.000 claims description 11
- 102000003729 Neprilysin Human genes 0.000 claims description 10
- 108090000028 Neprilysin Proteins 0.000 claims description 10
- 239000011521 glass Substances 0.000 claims description 10
- 230000005298 paramagnetic effect Effects 0.000 claims description 10
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 8
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 8
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 8
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 8
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 7
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 239000001384 succinic acid Substances 0.000 claims description 7
- 229920002307 Dextran Polymers 0.000 claims description 6
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims description 6
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 6
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108010010378 HLA-DP Antigens Proteins 0.000 claims description 5
- 102000015789 HLA-DP Antigens Human genes 0.000 claims description 5
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 claims description 5
- 102100026966 Thrombomodulin Human genes 0.000 claims description 5
- 102000007547 Laminin Human genes 0.000 claims description 4
- 108010085895 Laminin Proteins 0.000 claims description 4
- 239000012867 bioactive agent Substances 0.000 claims description 4
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 claims description 4
- 102000016942 Elastin Human genes 0.000 claims description 3
- 108010014258 Elastin Proteins 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 108010031318 Vitronectin Proteins 0.000 claims description 3
- 102100035140 Vitronectin Human genes 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000000919 ceramic Substances 0.000 claims description 3
- 229920002549 elastin Polymers 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- 101100042683 Arabidopsis thaliana SLAC1 gene Proteins 0.000 claims 1
- 102100037362 Fibronectin Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 625
- 210000004962 mammalian cell Anatomy 0.000 abstract description 7
- 210000001519 tissue Anatomy 0.000 description 106
- 239000002953 phosphate buffered saline Substances 0.000 description 69
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 68
- 239000006228 supernatant Substances 0.000 description 62
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 60
- 239000012091 fetal bovine serum Substances 0.000 description 60
- 230000005484 gravity Effects 0.000 description 58
- 230000001464 adherent effect Effects 0.000 description 42
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 41
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 41
- 238000003306 harvesting Methods 0.000 description 35
- 238000011081 inoculation Methods 0.000 description 32
- 239000002245 particle Substances 0.000 description 30
- 239000011324 bead Substances 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 25
- 239000002609 medium Substances 0.000 description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 23
- 239000008103 glucose Substances 0.000 description 23
- 210000004940 nucleus Anatomy 0.000 description 23
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 23
- 238000011534 incubation Methods 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 229910002091 carbon monoxide Inorganic materials 0.000 description 21
- 238000010899 nucleation Methods 0.000 description 19
- 239000012588 trypsin Substances 0.000 description 19
- 108010010803 Gelatin Proteins 0.000 description 18
- 102000004142 Trypsin Human genes 0.000 description 18
- 108090000631 Trypsin Proteins 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 230000035899 viability Effects 0.000 description 18
- 229920000159 gelatin Polymers 0.000 description 17
- 239000008273 gelatin Substances 0.000 description 17
- 235000019322 gelatine Nutrition 0.000 description 17
- 235000011852 gelatine desserts Nutrition 0.000 description 17
- 238000013341 scale-up Methods 0.000 description 16
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 16
- 238000012546 transfer Methods 0.000 description 16
- 241000508269 Psidium Species 0.000 description 15
- 238000004113 cell culture Methods 0.000 description 15
- 239000006285 cell suspension Substances 0.000 description 15
- 238000011031 large-scale manufacturing process Methods 0.000 description 15
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 15
- 102000018697 Membrane Proteins Human genes 0.000 description 14
- 108010052285 Membrane Proteins Proteins 0.000 description 14
- 238000000684 flow cytometry Methods 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 230000035755 proliferation Effects 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 12
- 238000011021 bench scale process Methods 0.000 description 12
- 238000011072 cell harvest Methods 0.000 description 12
- 238000009826 distribution Methods 0.000 description 12
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 11
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000012574 advanced DMEM Substances 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000000977 initiatory effect Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229930182555 Penicillin Natural products 0.000 description 8
- 238000010364 biochemical engineering Methods 0.000 description 8
- 239000012620 biological material Substances 0.000 description 8
- 229940049954 penicillin Drugs 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 238000007619 statistical method Methods 0.000 description 8
- 229960005322 streptomycin Drugs 0.000 description 8
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000012737 fresh medium Substances 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 238000000386 microscopy Methods 0.000 description 7
- 210000002826 placenta Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 229940014041 hyaluronate Drugs 0.000 description 6
- 239000003068 molecular probe Substances 0.000 description 6
- 230000007480 spreading Effects 0.000 description 6
- 238000003892 spreading Methods 0.000 description 6
- 239000012192 staining solution Substances 0.000 description 6
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 5
- 241001124532 Bubalus depressicornis Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000002458 cell surface marker Substances 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 238000013401 experimental design Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 230000001228 trophic effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000648 calcium alginate Substances 0.000 description 4
- 235000010410 calcium alginate Nutrition 0.000 description 4
- 229960002681 calcium alginate Drugs 0.000 description 4
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000005611 electricity Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000011045 prefiltration Methods 0.000 description 4
- 230000000405 serological effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000010094 cellular senescence Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- 210000001113 umbilicus Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 210000003771 C cell Anatomy 0.000 description 2
- 101150048775 CDI gene Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 2
- GKWTZACONBQTNK-IVIZKJKWSA-N N-benzyl-7H-purin-6-amine (1R,2R,5R,8R,9S,10R,12S)-12-hydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylic acid (1R,2R,5R,8R,9S,10R,12S)-12-hydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadec-13-ene-9-carboxylic acid Chemical compound C(Nc1ncnc2nc[nH]c12)c1ccccc1.CC12[C@H]3[C@H](C(O)=O)[C@@]45C[C@@H](CC[C@H]4[C@@]3(CC[C@@H]1O)OC2=O)C(=C)C5.CC12[C@H]3[C@H](C(O)=O)[C@@]45C[C@@H](CC[C@H]4[C@]3(OC1=O)C=C[C@@H]2O)C(=C)C5 GKWTZACONBQTNK-IVIZKJKWSA-N 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 239000003517 fume Substances 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229960002385 streptomycin sulfate Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 239000011345 viscous material Substances 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 101100205030 Caenorhabditis elegans hars-1 gene Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 102100025929 Neuronal migration protein doublecortin Human genes 0.000 description 1
- 101710105341 Neuronal migration protein doublecortin Proteins 0.000 description 1
- 239000004107 Penicillin G sodium Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101000931422 Photobacterium phosphoreum Methenyltetrahydrofolate cyclohydrolase Proteins 0.000 description 1
- 108010084535 ProNectin F Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101000752546 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Transaminated amino acid decarboxylase Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 108010006886 Vitrogen Proteins 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007792 gaseous phase Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007959 normoxia Effects 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000019369 penicillin G sodium Nutrition 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000008943 replicative senescence Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 108010048090 soybean lectin Proteins 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000002948 striated muscle cell Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000013337 sub-cultivation Methods 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 229920000208 temperature-responsive polymer Polymers 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000001644 umbilical artery Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 210000002965 wolffian duct Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/16—Particles; Beads; Granular material; Encapsulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2531/00—Microcarriers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Immunology (AREA)
- Sustainable Development (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86555806P | 2006-11-13 | 2006-11-13 | |
| US60/865,558 | 2006-11-13 | ||
| PCT/US2007/023846 WO2008060541A2 (en) | 2006-11-13 | 2007-11-13 | In vitro expansion of postpartum-derived cells using microcarriers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2007319820A1 AU2007319820A1 (en) | 2008-05-22 |
| AU2007319820B2 true AU2007319820B2 (en) | 2013-09-05 |
Family
ID=39402235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007319820A Ceased AU2007319820B2 (en) | 2006-11-13 | 2007-11-13 | In vitro expansion of postpartum-derived cells using microcarriers |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9102915B2 (https=) |
| EP (1) | EP2089511B1 (https=) |
| JP (2) | JP5670053B2 (https=) |
| CN (1) | CN101611139B (https=) |
| AU (1) | AU2007319820B2 (https=) |
| CA (1) | CA2669589C (https=) |
| ES (1) | ES2524443T3 (https=) |
| PL (1) | PL2089511T3 (https=) |
| WO (1) | WO2008060541A2 (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL159895A0 (en) * | 2001-07-20 | 2004-06-20 | Technion Res & Dev Foundation | Methods of generating human cardiac cells and tissues and uses thereof |
| US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
| US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
| US8518390B2 (en) | 2003-06-27 | 2013-08-27 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells |
| US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
| US7875272B2 (en) | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
| EP2399990B1 (en) | 2003-06-27 | 2015-07-22 | DePuy Synthes Products, Inc. | Cells derived from post-partum umbilical cord for use in treatment of disease of the heart and circulatory system |
| US8491883B2 (en) | 2003-06-27 | 2013-07-23 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
| CA2589041C (en) | 2004-12-23 | 2019-08-20 | DePuy Synthes Products, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
| EP1835924B1 (en) | 2004-12-23 | 2013-08-21 | Ethicon, Incorporated | Treatment of parkinson's disease and related disorders using postpartum derived cells |
| NZ597304A (en) | 2005-10-13 | 2013-06-28 | Anthrogenesis Corp | Immunomodulation using placental stem cells |
| WO2007070870A1 (en) | 2005-12-16 | 2007-06-21 | Ethicon, Inc. | Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
| US8741638B2 (en) * | 2005-12-19 | 2014-06-03 | DePuy Synthes Products, LLC | In vitro expansion of postpartum-derived cells in roller bottles |
| US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
| PL2471907T3 (pl) | 2005-12-29 | 2019-07-31 | Celularity, Inc. | Populacje komórek macierzystych łożyska |
| CN101595212B (zh) | 2006-10-12 | 2014-04-30 | 伊西康公司 | 肾源细胞及在组织修复和再生中的使用方法 |
| CN101611139B (zh) | 2006-11-13 | 2012-07-04 | 伊西康公司 | 利用微载体的产后来源的细胞的体外扩增 |
| NZ612888A (en) | 2007-02-12 | 2015-02-27 | Anthrogenesis Corp | Treatment of inflammatory diseases using placental stem cells |
| JP5350364B2 (ja) * | 2007-04-28 | 2013-11-27 | ヒョンジン ヤン， | 粉末状の足場を用いた細胞間の信号調節による細胞培養方法 |
| RU2536242C2 (ru) | 2007-09-28 | 2014-12-20 | Антродженезис Корпорейшн | Угнетение опухолей с помощью плацентарного перфузата человека и выделенных из плаценты человека вспомогательных натуральных клеток-киллеров |
| PT103843B (pt) * | 2007-10-04 | 2008-08-12 | Medinfar Produtos Farmaceutico | Método de isolamento de células precursoras a partir do cordão umbilical humano |
| ES2525718T3 (es) | 2007-10-05 | 2014-12-29 | DePuy Synthes Products, LLC | Reparación y regeneración de tejido renal mediante células derivadas de tejido de cordón umbilical humano |
| US8236538B2 (en) * | 2007-12-20 | 2012-08-07 | Advanced Technologies And Regenerative Medicine, Llc | Methods for sterilizing materials containing biologically active agents |
| US20090233334A1 (en) * | 2008-03-11 | 2009-09-17 | Excellgene Sa | Cell cultivation and production of recombinant proteins by means of an orbital shake bioreactor system with disposable bags at the 1,500 liter scale |
| US20120219531A1 (en) * | 2008-03-17 | 2012-08-30 | Agency For Science, Technology And Research | Microcarriers for Stem Cell Culture |
| US8828720B2 (en) * | 2008-03-17 | 2014-09-09 | Agency For Science, Technology And Research | Microcarriers for stem cell culture |
| US20120028352A1 (en) * | 2008-03-17 | 2012-02-02 | Agency For Science, Technology And Research | Microcarriers for Stem Cell Culture |
| SG188918A1 (https=) | 2008-03-17 | 2013-04-30 | Agency Science Tech & Res | |
| US8691569B2 (en) * | 2008-03-17 | 2014-04-08 | Agency For Science, Technology And Research | Microcarriers for stem cell culture |
| US9458431B2 (en) | 2008-03-17 | 2016-10-04 | Agency For Science, Technology And Research | Microcarriers for stem cell culture |
| CA2734237C (en) | 2008-08-20 | 2019-07-02 | Anthrogenesis Corporation | Treatment of stroke using isolated placental cells |
| KR20200011604A (ko) | 2008-08-20 | 2020-02-03 | 안트로제네시스 코포레이션 | 개선된 세포 조성물 및 그의 제조 방법 |
| CA2734446C (en) | 2008-08-22 | 2017-06-20 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
| RU2015130665A (ru) | 2008-11-19 | 2018-12-24 | Антродженезис Корпорейшн | Амниотические адгезивные клетки |
| US20100151575A1 (en) * | 2008-12-15 | 2010-06-17 | Colter David C | Method of Making Conditioned Media from Kidney Derived Cells |
| US10179900B2 (en) | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
| JP5518893B2 (ja) | 2008-12-19 | 2014-06-11 | アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー | 肺ならびに肺の疾患および障害の治療 |
| EP2411504B1 (en) | 2009-03-26 | 2017-05-10 | DePuy Synthes Products, Inc. | Human umbilical cord tissue cells as therapy for alzheimer's disease |
| US20100247495A1 (en) * | 2009-03-30 | 2010-09-30 | Tom Ichim | Treatment of Muscular Dystrophy |
| WO2011016829A1 (en) * | 2009-08-06 | 2011-02-10 | Albert Einstein College Of Medicine Of Yeshiva University | Cell therapy for treatment of liver failure |
| US8278101B2 (en) * | 2009-12-07 | 2012-10-02 | Synthecon, Inc. | Stem cell bioprocessing and cell expansion |
| DK3284818T3 (da) | 2010-01-26 | 2022-06-20 | Celularity Inc | Behandling af knoglerelateret kræft ved hjælp af placenta stamceller |
| DK2556145T3 (en) | 2010-04-07 | 2016-11-07 | Anthrogenesis Corp | Angiogenesis using placental stem cells |
| EP2555783A1 (en) | 2010-04-08 | 2013-02-13 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
| JP5947790B2 (ja) * | 2010-05-25 | 2016-07-06 | クック・バイオテック・インコーポレイテッドＣｏｏｋ Ｂｉｏｔｅｃｈ Ｉｎｃｏｒｐｏｒａｔｅｄ | 医療用移植片の細胞播種に有用な方法、基質、およびシステム |
| CN102146356A (zh) * | 2010-06-24 | 2011-08-10 | 辽宁成大生物股份有限公司 | 一种再生微载体的方法 |
| MX342995B (es) | 2010-07-13 | 2016-10-21 | Anthrogenesis Corp | Métodos de generar células asesinas naturales. |
| US10240121B2 (en) | 2010-08-16 | 2019-03-26 | Kiyatec Inc. | Bioreactor system |
| WO2012092485A1 (en) | 2010-12-31 | 2012-07-05 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory rna molecules |
| JP2012165719A (ja) * | 2011-02-16 | 2012-09-06 | National Institute Of Advanced Industrial Science & Technology | 擬微小重力環境下での三次元癌組織モデルの構築方法 |
| ES2707579T3 (es) | 2011-06-01 | 2019-04-04 | Celularity Inc | Tratamiento del dolor usando citoblastos placentarios |
| US20140170748A1 (en) * | 2012-12-14 | 2014-06-19 | DePuy Synthes Products, LLC | Nutrient Enriched Media for hUTC Growth |
| AU2014215458A1 (en) | 2013-02-05 | 2015-08-13 | Anthrogenesis Corporation | Natural killer cells from placenta |
| CN108663344A (zh) * | 2013-02-19 | 2018-10-16 | 艾博特健康公司 | 分析生物流体样品的方法 |
| CA2917073A1 (en) * | 2013-06-24 | 2014-12-31 | Anthrogenesis Corporation | Extracellular matrix composition beads for cell culture |
| WO2017112455A2 (en) * | 2015-12-22 | 2017-06-29 | Corning Incorporated | Cell separation device and method for using same |
| US10791730B2 (en) | 2016-01-14 | 2020-10-06 | DePuy Synthes Products, Inc. | Composition and methods for cryopreservation of hUTC |
| PL3464550T3 (pl) | 2016-05-31 | 2020-06-15 | Corning Incorporated | Naczynia i kolby typu spinner z redukcją chybotania wirnika do hodowli komórek |
| WO2018075940A1 (en) * | 2016-10-21 | 2018-04-26 | Georgia Tech Research Corporation | Methods and systems for t cell expansion |
| JP6995112B2 (ja) | 2017-04-06 | 2022-02-04 | 日機装株式会社 | 細胞の培養方法及び細胞支持複合体の製造方法 |
| WO2019181920A1 (ja) * | 2018-03-22 | 2019-09-26 | 日機装株式会社 | 細胞の培養方法、細胞支持複合体の製造方法、培養細胞および細胞支持複合体 |
| KR20210134323A (ko) * | 2019-01-31 | 2021-11-09 | 베이징 사이토니체 바이오테크놀로지 씨오., 엘티디. | 줄기 세포의 대규모 제조를 위한 3차원 배양 방법 |
| CN111424011A (zh) * | 2020-04-17 | 2020-07-17 | 深圳市旷逸生物科技有限公司 | 一种能够维持脐带间充质干细胞细胞形态的三维培养方法 |
| WO2022060015A1 (ko) * | 2020-09-15 | 2022-03-24 | 주식회사 엘지화학 | 세포 배양용 마이크로-캐리어 및 그 제조방법 |
| JPWO2024253069A1 (https=) * | 2023-06-06 | 2024-12-12 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005001080A2 (en) * | 2003-06-27 | 2005-01-06 | Ethicon, Incorporated | Postpartum-derived cells for use in treatment of disease of the heart and circulatory system |
| WO2006027229A1 (de) * | 2004-09-07 | 2006-03-16 | Rheinische Friedrich-Wilhelms- Universität | Skalierbarer prozess zur kultivierung undifferenzierter stammzellen in suspension |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1220832B (de) * | 1964-09-22 | 1966-07-14 | Siemens Ag | Ziehduese zum Ziehen von Halbleiterkristallen aus einer Schmelze |
| US3665061A (en) | 1969-07-16 | 1972-05-23 | United States Banknote Corp | Process for producing collagen sponges |
| US4216144A (en) | 1977-10-20 | 1980-08-05 | Ashmead H H | Soluble iron proteinates |
| JPS6040439B2 (ja) | 1978-03-29 | 1985-09-11 | 大正製薬株式会社 | ヒドロコルチゾン誘導体 |
| US4487865A (en) | 1983-12-15 | 1984-12-11 | Biomatrix, Inc. | Polymeric articles modified with hyaluronate |
| US5266476A (en) * | 1985-06-18 | 1993-11-30 | Yeda Research & Development Co., Ltd. | Fibrous matrix for in vitro cell cultivation |
| US5266480A (en) * | 1986-04-18 | 1993-11-30 | Advanced Tissue Sciences, Inc. | Three-dimensional skin culture system |
| US4963489A (en) * | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
| US4925677A (en) | 1988-08-31 | 1990-05-15 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
| US5284766A (en) * | 1989-02-10 | 1994-02-08 | Kao Corporation | Bed material for cell culture |
| NL9100038A (nl) | 1991-01-11 | 1992-08-03 | Stamicarbon | Enzym-gekatalyseerde bereiding van optisch aktieve carbonzuren. |
| DE4406073A1 (de) | 1994-02-24 | 1995-08-31 | Univ Ludwigs Albert | Verfahren zur Herstellung von humanen, klonogenen Fibroblasten, Verfahren zur Gentransfizierung von Fibroblasten und so erhaltene Fibroblasten |
| US5919702A (en) | 1996-10-23 | 1999-07-06 | Advanced Tissue Science, Inc. | Production of cartilage tissue using cells isolated from Wharton's jelly |
| EP0983062A4 (en) | 1997-05-21 | 2002-10-23 | Sloan Kettering Inst Cancer | METHOD FOR INCREASING THE CONCENTRATION OF ASCOBIC ACID IN PERSONAL BRAIN TISSUE |
| US7560280B2 (en) | 2000-11-03 | 2009-07-14 | Kourion Therapeutics Gmbh | Human cord blood derived unrestricted somatic stem cells (USSC) |
| EP2316918B1 (en) | 2001-02-14 | 2015-07-01 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| ATE456664T1 (de) | 2001-04-02 | 2010-02-15 | Glycomedics Inc | Verfahren zur herstellung von oligosaccharidketten |
| WO2003065999A2 (en) * | 2002-02-08 | 2003-08-14 | University Of South Florida | Proliferated cell lines and uses thereof |
| EP1483371B1 (en) | 2002-02-19 | 2007-06-27 | Medipost, Co., Ltd. | Isolation and culture-expansion methods of mesenchymal stem/progenitor cells from umbilical cord blood, and differentiation method of umbilical cord blood-derived mesenchymal stem/progenitor cells into various mesenchymal tissues |
| JP2003259862A (ja) * | 2002-03-12 | 2003-09-16 | Fuji Photo Film Co Ltd | 細胞培養担体 |
| AU2003265094A1 (en) | 2002-08-26 | 2004-03-11 | Neuronova Ab | Method for culturing stem cells |
| GB0222846D0 (en) * | 2002-10-03 | 2002-11-06 | Choo Yen | Cell culture |
| US7875272B2 (en) * | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
| US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
| US8790637B2 (en) * | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
| AU2004260106C1 (en) | 2003-07-17 | 2010-12-09 | Global Cell Solutions, Llc. | Automated cell culture system and process |
| JP4575654B2 (ja) * | 2003-09-05 | 2010-11-04 | エスエス製薬株式会社 | 溶解性と流動性を改善した医薬組成物 |
| EP1812557A4 (en) | 2004-10-29 | 2009-11-04 | Centocor Ortho Biotech Inc | COMPOSITIONS OF CHEMICALLY DEFINED MEDIA |
| US20060166361A1 (en) | 2004-12-21 | 2006-07-27 | Agnieszka Seyda | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same |
| CA2589041C (en) * | 2004-12-23 | 2019-08-20 | DePuy Synthes Products, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
| EP1835924B1 (en) * | 2004-12-23 | 2013-08-21 | Ethicon, Incorporated | Treatment of parkinson's disease and related disorders using postpartum derived cells |
| WO2006088867A2 (en) * | 2005-02-15 | 2006-08-24 | Medistem Laboratories, Incorporated | Method for expansion of stem cells |
| CN103361301A (zh) * | 2005-03-31 | 2013-10-23 | 斯丹姆涅恩有限公司 | 高度纯化来自羊膜的细胞群 |
| WO2007070870A1 (en) * | 2005-12-16 | 2007-06-21 | Ethicon, Inc. | Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
| US8741638B2 (en) * | 2005-12-19 | 2014-06-03 | DePuy Synthes Products, LLC | In vitro expansion of postpartum-derived cells in roller bottles |
| EP2548951B1 (en) | 2006-03-23 | 2016-05-04 | Pluristem Ltd. | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
| ES2610812T3 (es) | 2006-06-26 | 2017-05-03 | Lifescan, Inc. | Cultivo de células madre pluripotentes |
| CN101611139B (zh) | 2006-11-13 | 2012-07-04 | 伊西康公司 | 利用微载体的产后来源的细胞的体外扩增 |
| US10179900B2 (en) * | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
| CN102458425A (zh) | 2008-12-19 | 2012-05-16 | 伊西康公司 | 损伤后神经组织的再生和修复 |
| EP2379087B1 (en) | 2008-12-19 | 2014-08-20 | DePuy Synthes Products, LLC | Umbilical cord tissue derived cells for treating neuropathic pain and spasticity |
| EP2411504B1 (en) * | 2009-03-26 | 2017-05-10 | DePuy Synthes Products, Inc. | Human umbilical cord tissue cells as therapy for alzheimer's disease |
-
2007
- 2007-11-13 CN CN2007800494226A patent/CN101611139B/zh not_active Expired - Fee Related
- 2007-11-13 EP EP07867434.8A patent/EP2089511B1/en not_active Not-in-force
- 2007-11-13 ES ES07867434.8T patent/ES2524443T3/es active Active
- 2007-11-13 JP JP2009536337A patent/JP5670053B2/ja not_active Expired - Fee Related
- 2007-11-13 WO PCT/US2007/023846 patent/WO2008060541A2/en not_active Ceased
- 2007-11-13 PL PL07867434T patent/PL2089511T3/pl unknown
- 2007-11-13 AU AU2007319820A patent/AU2007319820B2/en not_active Ceased
- 2007-11-13 US US11/939,360 patent/US9102915B2/en not_active Expired - Fee Related
- 2007-11-13 CA CA2669589A patent/CA2669589C/en not_active Expired - Fee Related
-
2014
- 2014-09-26 JP JP2014196523A patent/JP2014236755A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005001080A2 (en) * | 2003-06-27 | 2005-01-06 | Ethicon, Incorporated | Postpartum-derived cells for use in treatment of disease of the heart and circulatory system |
| WO2006027229A1 (de) * | 2004-09-07 | 2006-03-16 | Rheinische Friedrich-Wilhelms- Universität | Skalierbarer prozess zur kultivierung undifferenzierter stammzellen in suspension |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014236755A (ja) | 2014-12-18 |
| AU2007319820A1 (en) | 2008-05-22 |
| EP2089511A2 (en) | 2009-08-19 |
| WO2008060541A2 (en) | 2008-05-22 |
| CN101611139A (zh) | 2009-12-23 |
| US20080166328A1 (en) | 2008-07-10 |
| EP2089511B1 (en) | 2014-09-17 |
| JP2010508851A (ja) | 2010-03-25 |
| ES2524443T3 (es) | 2014-12-09 |
| US9102915B2 (en) | 2015-08-11 |
| CA2669589C (en) | 2016-01-12 |
| CN101611139B (zh) | 2012-07-04 |
| WO2008060541A3 (en) | 2008-08-28 |
| JP5670053B2 (ja) | 2015-02-18 |
| CA2669589A1 (en) | 2008-05-22 |
| PL2089511T3 (pl) | 2015-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007319820B2 (en) | In vitro expansion of postpartum-derived cells using microcarriers | |
| JP2010508851A5 (https=) | ||
| Li et al. | 3D printing human induced pluripotent stem cells with novel hydroxypropyl chitin bioink: scalable expansion and uniform aggregation | |
| US11198849B2 (en) | Method for stem cell culture and cells derived therefrom | |
| Hookway et al. | Aggregate formation and suspension culture of human pluripotent stem cells and differentiated progeny | |
| KR102151588B1 (ko) | hUTC 성장을 위한 영양 강화 배지 | |
| JP2012509085A (ja) | マイクロキャリア上での多能性幹細胞の培養 | |
| US20220395537A1 (en) | Methods of stem cell culture for obtaining products, and implementations thereof | |
| JP2022523129A (ja) | 幹細胞の大規模調製のための三次元培養方法 | |
| JP2021509812A (ja) | 巨核球を産生するための組成物および方法 | |
| JP2023134611A (ja) | 細胞懸濁液の製造方法、及び、接着細胞の製造方法 | |
| CN116426470B (zh) | 间充质干细胞无血清培养基及其应用 | |
| CN110951686A (zh) | 一种造血干细胞体外扩增培养体系和方法 | |
| CN118703430A (zh) | 一种基于可溶性微载体的干细胞球大规模制备方法 | |
| WO2005121319A1 (en) | Methods for production of mesodermal lineage cells | |
| WO2024134178A1 (en) | Cell culturing of adherent cells | |
| JP2026504736A (ja) | 培養方法 | |
| Xeno | Regine Eibl 3,‡, Michele Müller 2,‡ and Tiziano Tallone 1,*,‡ 1 Foundation for Cardiological Research and Education (FCRE), Cardiocentro Ticino Foundation, 6807 Taverne, Switzerland; francesco. muoio@ cardiocentro. org (FM); stefano. panella@ cardiocentro. org (SP); tiziano. moccetti@ cardiocentro. org (TM) 2 Sferalp SA, 6998 Monteggio, Switzerland; mlin@ sferalp. com (ML); mmul@ sferalp. com (MM) | |
| de Sousa Pinto | Maximizing human mesenchymal stem/stromal cells therapeutic potential through 3D cell cultivation | |
| Xeno et al. | Appl. Sci. 2021, 11, 925. https://doi. org/10.3390/app11030925 www. mdpi. com/journal/applsci | |
| Ibrahim et al. | Influence of medium composition and substratum on the growth of fli: GFP+ and kdrl: GFP+ cells in zebrafish blastocyst cell culture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE CO-INVENTOR FROM GOSEIWSKA, ANNA TO GOSIEWSKA, ANNA |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |